Fig. 1From: The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trialsProportion of migraine patients with headache relief (a decrease of headache from moderate or severe to none or mild) (HR) at 2 h after intravenous lasmiditan (PBO placebo) [15]Back to article page